Literature DB >> 9154175

Clinical development plan: phenethyl isothiocyanate.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9154175

Source DB:  PubMed          Journal:  J Cell Biochem Suppl        ISSN： 0733-1959


× No keyword cloud information.
  6 in total

1.  Pharmacokinetics of dietary phenethyl isothiocyanate in rats.

Authors:  Yan Ji; Yuhsin Kuo; Marilyn E Morris
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

2.  Dietary phenethylisothiocyanate attenuates bowel inflammation in mice.

Authors:  Moul Dey; Peter Kuhn; David Ribnicky; Vummidigiridhar Premkumar; Kenneth Reuhl; Ilya Raskin
Journal:  BMC Chem Biol       Date:  2010-04-27

3.  The inactivation of human CYP2E1 by phenethyl isothiocyanate, a naturally occurring chemopreventive agent, and its oxidative bioactivation.

Authors:  Yasushi Yoshigae; Chitra Sridar; Ute M Kent; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2013-01-31       Impact factor: 3.922

4.  Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells.

Authors:  Dan Wang; Bijaya Upadhyaya; Yi Liu; David Knudsen; Moul Dey
Journal:  BMC Cancer       Date:  2014-08-15       Impact factor: 4.430

5.  Phenethylisothiocyanate alters site- and promoter-specific histone tail modifications in cancer cells.

Authors:  Yi Liu; Suvobrata Chakravarty; Moul Dey
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

6.  Phytochemicals attenuating aberrant activation of β-catenin in cancer cells.

Authors:  Dan Wang; Mitchell L Wise; Feng Li; Moul Dey
Journal:  PLoS One       Date:  2012-12-03       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.